Hydrocortison Vuab (Hydrocortisone)

Hydrocortison Vuab is given by injection to provide rapid systemic glucocorticoid effects for medical situations that require prompt anti‑inflammatory or immunosuppressive action.

• Management of acute adrenal crisis or primary adrenal insufficiency when oral therapy is insufficient.
• Treatment of severe anaphylactic or allergic reactions that do not respond to standard emergency measures.
• Control of acute asthma exacerbations or chronic obstructive pulmonary disease flare‑ups requiring systemic steroids.
• Reduction of inflammation in severe rheumatic, dermatologic, or autoimmune disorders such as lupus or vasculitis.
• Supportive therapy for septic or hemorrhagic shock where cortisol levels are critically low.

• Hydrocortison Vuab delivers hydrocortisone, a synthetic analogue of endogenous cortisol, which diffuses across cell membranes and binds to intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus, where it interacts with glucocorticoid response elements, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokines. This genomic effect reduces leukocyte migration, capillary permeability, and fibroblast proliferation, producing systemic anti‑inflammatory and immunosuppressive actions.

Systemic administration of hydrocortisone can be associated with a range of adverse reactions, which vary in frequency and severity.

Common

• Elevated blood glucose levels, especially in patients with diabetes.
• Mild fluid retention leading to peripheral edema.
• Transient increase in blood pressure.
• Insomnia or difficulty sleeping.
• Mood swings or mild anxiety.
• Gastrointestinal discomfort such as nausea.

Serious

• Adrenal suppression causing secondary adrenal insufficiency on abrupt discontinuation.
• Increased susceptibility to severe infections.
• Marked hypertension or cardiovascular events.
• Psychiatric disturbances including severe depression or psychosis.
• Allergic reactions ranging from rash to anaphylaxis.
• Avascular necrosis of bone with prolonged high‑dose therapy.

Before using Hydrocortison Vuab, healthcare professionals should evaluate several clinical factors to minimize risks and ensure appropriate therapy.

• Avoid use in patients with systemic fungal infections unless antifungal therapy is initiated.
• Exercise caution in individuals with uncontrolled diabetes, as hyperglycemia may worsen.
• Monitor blood pressure closely in patients with pre‑existing hypertension.
• Use carefully in those with a history of peptic ulcer disease or gastrointestinal bleeding.
• Assess risks versus benefits during pregnancy and lactation; data are limited.
• Screen for active infections and consider prophylactic measures when immunosuppression is anticipated.

Hydrocortison Vuab may interact with other medicines, altering its effectiveness or increasing adverse effects.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) may markedly reduce hydrocortisone levels.
• Co‑administration with high‑dose NSAIDs or anticoagulants can increase risk of gastrointestinal bleeding.

Use with caution

• Combination with other systemic corticosteroids may enhance immunosuppression and adrenal suppression.
• Concurrent use of antidiabetic agents may require dose adjustments due to hyperglycemia.
• Concurrent use with antihypertensive drugs may necessitate blood pressure monitoring.
• Vaccinations, especially live vaccines, should be timed appropriately when on systemic steroids.